Quick Answer: Private label cosmetics for South Korea need a product-specific compliance handover between the manufacturer, brand and registered Korean responsible cosmetic distributor. Agree formula access, Korean artwork approval, functional-product responsibilities where applicable, batch release and change control before paying for printed packaging. A private label contract assigns work and access rights; it does not replace Korean registration, product-route decisions or statutory quality and safety duties.
Define the private label model before requesting a quotation
Private label can mean an existing supplier formula with your artwork, a modified base formula, or a development project with negotiated exclusivity. These models have different evidence and ownership consequences. Describe the chosen model in the product brief instead of assuming that a branded bottle means the brand owns the underlying formulation.
For Korea, add the intended product name, sales channels, use area, target users, claims and pack sizes. Identify whether the finished goods will be made overseas and imported or manufactured in Korea. This guide focuses on commercial private label supply and the agreement supporting Korean market release. Personal imports and customised cosmetic operations require separate assessment.
Ask for a quotation that separates formula development, testing, packaging, Korean review, production and logistics. A low unit price can leave critical technical work outside scope. Record each excluded task and its owner before comparing suppliers. Use the OEM/ODM cosmetics manufacturing guide to frame the manufacturing discussion, then add Korea-specific decisions to the project schedule.
| Workstream | Manufacturer | Brand and Korean operator |
|---|---|---|
| Formula | Accurate composition and controlled production revision | Confidential access and Korean suitability review |
| Artwork | Pack specifications and print implementation | Korean particulars, claims and final approval |
| Quality | Specifications, batch records and investigations | Applicable inspection and local release |
| Continuing supply | Advance change notices and technical support | Impact decisions, complaints and market response |
Verify the Korean responsible distributor as a separate role
Article 3 of the Cosmetics Act in force from 20 October 2026 distinguishes manufacturing registration from responsible cosmetic distribution registration. Confirm the registered entity, responsible distribution management and practical quality capability for the planned operation. A foreign factory, brand owner, sales agent and Korean importer may be different legal entities; give each one an explicit place in the agreement.
The current Act is the starting point, but its database can also display future provisions. Do not apply amendments marked for 27 November 2026 or 2027 as though they were already effective on this review date. Ask the local reviewer to check the effective provisions again for the actual import and sales dates.
Require a named local contact for release, complaints and urgent safety questions. Confirm how the partner will obtain confidential supplier information and how it will reconcile incoming stock with sales. Our South Korea market-entry guide discusses the wider operating model; the private label contract should convert that model into document access, approvals and delivery milestones.
Negotiate formula rights and confidentiality precisely
Separate ownership, permitted use, exclusivity and disclosure. An existing stock formula can remain the manufacturer’s property while the brand receives a limited right to sell agreed products. A development fee does not by itself establish ownership or unrestricted transfer rights. State the territory, duration, product scope and consequences of termination in language that the commercial and technical teams can both use.
The Korean reviewer needs sufficiently detailed composition to assess the product. Agree a confidentiality route that allows necessary disclosure to the responsible distributor, competent reviewer or authority while protecting supplier know-how. Include quantitative composition, premix constituents, ingredient identity and relevant material specifications. A trade-name ingredient list alone can prevent a reliable assessment.
Specify whether the brand can appoint a replacement manufacturer and what technical information may be transferred. Distinguish access to an existing dossier from a right to reproduce the formula. If the supplier will not permit a transfer, understand that limitation before committing to brand claims, packaging inventory or an exclusive distribution arrangement.
Keep one signed formula reference tied to the approved sample. Add an internal revision identifier, manufacturing site and agreed specifications. Future purchase orders should reference that baseline. The approved smell or texture of a sample is useful, but it does not identify every constituent or establish that later batches use the same composition.
| Contract topic | Useful agreement | Handover evidence |
|---|---|---|
| Formula rights | Who owns it and who may use or transfer it | Signed formula reference and disclosure permissions |
| Artwork rights | Ownership of files, translations and packaging tools | Editable masters and final approved print proof |
| Regulatory records | Holder, access rights and lawful transfer steps | Dossier index and copies where permitted |
| Exit support | Timing, fees and cooperation duties | Document inventory, stock and complaint handover |
Resolve ordinary or functional positioning before artwork
The MFDS cosmetics process overview describes examination or reporting for functional cosmetics. Have the Korean reviewer assess the complete intended use and presentation, including product name, pack and online claims. Do not assume a stock formula has a reusable Korean functional status merely because the supplier sells a similar product elsewhere.
For a functional product, identify the relevant examination or reporting route, the holder or submitting party, the product match and required supporting evidence. Confirm whether any proposed formula, brand name or manufacturing change affects that route. Put the resulting tasks and costs in the agreement rather than treating them as a generic approval service.
For an ordinary cosmetic, record the accepted claims boundary and technical assessment. Ordinary status does not remove ingredient, quality, labelling or advertising duties. Avoid universal statements such as every cosmetic needs MFDS approval. Business registration, ingredient-list reporting and functional-product procedures answer different questions and should have separate evidence entries.
Build a dossier handover that can support local decisions
Use a document schedule with creator, recipient, revision and due date. At minimum, request the final formula information, site details, specifications, relevant finished-product evidence, packaging information and batch documentation needed for the local assessment. Mark documents as available, pending, conditional or excluded. A planned test should never appear in the file as a completed result.
Agree the product and sample identity on each report. Stability, microbiological quality, preservation and pack compatibility evidence may be relevant depending on the formula, use and packaging. The local reviewer should determine the actual gaps and applicability. Evidence generated for a different pack or formula requires a reasoned assessment before it supports this SKU.
The responsible distributor duties in Enforcement Rule Article 12 address quality management, post-sale safety, manufacturing and quality records, imported product records and batch quality inspection. They also address oversight when work is outsourced. These duties explain why the Korean operator needs continuing technical cooperation beyond delivery of a marketing brochure.
The Korean regulatory framework guide sets out the broader layers. For a private label project, use those layers as acceptance criteria: which documents must be accepted before a deposit, artwork approval, shipment and release? State who resolves an incomplete file and what happens to production dates while a question remains open.
Control Korean artwork and packaging assets
The current Article 10 packaging particulars provides the statutory starting point for information such as product identity, business details, ingredients, quantity, batch identification, use period and precautions, with detailed rules and packaging exceptions. The Korean reviewer should determine the exact particulars and placement for the commercial pack. Treat this as a full packaging assessment rather than an ingredient-list translation task.
Agree who commissions and owns the Korean translation, editable design files, print tooling and finished artwork. Keep supplier technical input separate from brand marketing approval and local regulatory review. The final approval should identify the precise file, formula revision, pack size and date, so production does not accidentally use an earlier proof.
Review the joined Korean text and the complete primary and outer pack together. Check readable print size, contrast, coding area and the smallest pack. If a packaging supplier changes the label dimensions, material or finish, reopen the practical readability check before printing. Retain a finished pack photograph alongside the approved proof.
Extend the same control to product listings, influencer briefs and retailer copy. A brand may own the creative assets while the Korean operator needs authority to stop misleading claims. Specify the review and escalation process, particularly when promotional language changes the intended product positioning.
| Milestone | Evidence to accept | Reason to pause |
|---|---|---|
| Before printed packaging | Formula baseline and approved Korean artwork | Unresolved claims or business particulars |
| Before shipment | Agreed technical and commercial documents | Missing batch identity or required import evidence |
| Before local sale | Applicable import, quality and release records | Inspection question or pack mismatch |
| Before repeat order | Approved change review and current specification | Unnotified substitution or new claims |
Make batch release and change control part of supply
Agree specifications, sampling, testing, deviations and acceptance before the first production run. Distinguish the manufacturer’s production release from the Korean responsible distributor’s local release responsibilities. A certificate of analysis is useful evidence, but the local operator must determine the applicable inspection arrangement and any legal exception it relies on.
Prohibit unreviewed substitutions in the commercial agreement. A new fragrance blend, preservative supplier, manufacturing site, process, bottle resin or pump may affect the assessment even when the product looks unchanged. Require advance notice describing the change, affected SKUs, proposed implementation batch and supporting evidence. Set a response process for both routine and urgent changes.
Record whether the change affects formula screening, functional records, testing, artwork, import documents or existing inventory. Define how old and new revisions will be distinguished in stock. Purchase approval should not silently substitute for the local compliance decision; preserve a written conclusion that another reviewer can follow.
Keep retain samples and traceability arrangements proportionate to the product and applicable duties. Reconcile batch quantities across manufacture, import, release, sales, returns and destruction. This makes a complaint investigation practical and helps the parties identify the scope of a distribution hold.
Plan complaints, termination and a replacement partner
Set a complaint escalation procedure with responsible people, contact routes and the information required from the consumer. Link reports to product and batch whenever possible. The manufacturer should support technical investigation, while the Korean operator assesses local safety reporting and market action. Contractual deadlines should support those duties and should not delay urgent action.
Prepare an exit schedule before the relationship deteriorates. List regulatory records, approved artwork, open complaints, unsold stock, batch histories, samples and outstanding investigations. Confirm which materials can be transferred and which legal steps a replacement distributor must complete. Changing a commercial partner does not automatically transfer registrations, product records or permission to use a supplier formula.
For a project discussion, contact the manufacturing team with the product brief, proposed Korean operating partner and a document gap list. Ask for product-specific evidence and responsibilities. Any Korean licences, functional status or local representation should be verified for the actual entity and product; this guide does not claim that MOOYAM holds those Korean authorisations.
Frequently asked questions
Does a private label supplier’s certificate cover the Korean launch?
No single generic certificate establishes the entire route. Verify the actual product, business roles, formula evidence, functional procedure where applicable, packaging and local release records.
Who should own the formula?
That is a negotiated commercial decision. Define ownership, permitted use, exclusivity, disclosure and transfer separately, and ensure the Korean reviewer can obtain necessary technical information.
Can we reuse an existing Korean functional product record?
Do not assume so. Have the local reviewer verify the record, holder, product match and applicable amendment or new submission requirements before relying on it.
Who approves the Korean packaging?
The brand coordinates commercial artwork with the manufacturer’s technical input and competent Korean review. Keep the approved final file linked to the actual formula, size and business entities.
What happens when the Korean distributor changes?
Use a documented handover of records, stock and open issues. Confirm applicable registration and product-record steps and contractual disclosure permissions before the replacement operator releases stock.
Last reviewed: 27 October 2026. General planning information, not product-specific legal or safety advice. Confirm current Korean requirements and contract terms with qualified local advisers before manufacture, import or sale.